Barclays on Watson Pharmaceuticals (WPI): Milestone Hit, Feeling Comfort Through 2014
Tweet Send to a FriendGet Alerts WPI Hot Sheet
Price: $85.73 --0%
Rating Summary:
14 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 35 | New: 12
Rating Summary:
14 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 35 | New: 12
Trade WPI Now!
Barclays maintains an 'Overweight' on Watson Pharmaceuticals (NYSE: WPI) price target of $80.00.
Analyst, Douglas D. Tsao, said, "We believe WPI's approval for its generic version of pain-patch Lidoderm (transdermal lidocaine) is an important milestone by providing greater visibility on the strength of its underlying business. Investors have been willing to give WPI credit for the earnings accretion from Actavis, but concerns regarding organic growth of the underlying business resulted in WPI shares trading at an earnings multiple not fully reflective of the company's expected growth. However, this approval, as well as Actavis' approval of Adderall XR, should provide comfort regarding the opportunities for WPI's generics business through 2014."
For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.
Shares of Watson Pharmaceuticals closed at $78.63 yesterday, with a 52 week range of $55.00-$81.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Douglas D. Tsao, said, "We believe WPI's approval for its generic version of pain-patch Lidoderm (transdermal lidocaine) is an important milestone by providing greater visibility on the strength of its underlying business. Investors have been willing to give WPI credit for the earnings accretion from Actavis, but concerns regarding organic growth of the underlying business resulted in WPI shares trading at an earnings multiple not fully reflective of the company's expected growth. However, this approval, as well as Actavis' approval of Adderall XR, should provide comfort regarding the opportunities for WPI's generics business through 2014."
For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.
Shares of Watson Pharmaceuticals closed at $78.63 yesterday, with a 52 week range of $55.00-$81.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: BTIG Starts ING U.S (VOYA) at Buy, Shares 'Significantly Undervalued'
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, FDARelated Entities
Barclays, Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
